Top

Cancer Chemotherapy and Pharmacology

Published in:

01-07-2010 | Original Article

Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic meta-analysis

Authors: Brett E. Houk, Carlo L. Bello, Bill Poland, Lee S. Rosen, George D. Demetri, Robert J. Motzer

Published in: Cancer Chemotherapy and Pharmacology | Issue 2/2010

Abstract

Purpose

In this pharmacokinetic/pharmacodynamic meta-analysis, we investigated relationships between clinical endpoints and sunitinib exposure in patients with advanced solid tumors, including patients with gastrointestinal stromal tumor (GIST) and metastatic renal cell carcinoma (mRCC).

Methods

Pharmacodynamic data were available for 639 patients of whom 443 had pharmacokinetic data. Sunitinib doses ranged from 25 to 150 mg QD or QOD. Models to express endpoint values and/or changes from baseline by the highest-correlating exposure measures were developed in S-PLUS or NONMEM using fixed- and mixed-effects modeling.

Results

Tentative relationships were identified between (1) steady-state AUC of total drug (sunitinib + its active metabolite SU12662) and time to tumor progression (TTP), overall survival (OS), with AUC significantly associated with longer TTP and OS in patients with GIST and mRCC, and incidence, but not severity, of fatigue; (2) steady-state AUC of sunitinib and response probability, with AUC significantly associated with objective response in patients with mRCC and stable disease in patients with both mRCC and GIST (with no such correlations in patients with solid tumors); (3) dose and tumor size reductions; (4) total drug concentration and diastolic blood pressure (DBP), with a typical patient on sunitinib 50 mg QD (the recommended dose) predicted to experience a maximum DBP increase of 8 mmHg; and (5) cumulative AUC of total drug and absolute neutrophil count (ANC), with ANC reductions occurring predominantly after one treatment cycle.

Conclusions

The results of this meta-analysis indicate that increased exposure to sunitinib is associated with improved clinical outcomes (longer TTP, longer OS, greater chance of antitumor response), as well as some increased risk of adverse effects. A sunitinib 50-mg starting dose seems reasonable, providing clinical benefit with acceptably low risk of adverse events.

Abrams TJ, Lee LB, Murray LJ et al (2003) SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer. Mol Cancer Ther 2:471–478PubMed

Faivre S, Delbaldo C, Vera K et al (2006) Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol 24:25–35CrossRefPubMed

O’Farrell AM, Foran JM, Fiedler W et al (2003) An innovative phase I clinical study demonstrates inhibition of FLT3 phosphorylation by SU11248 in acute myeloid leukemia patients. Clin Cancer Res 9:5465–5476PubMed

Kim DW, Jo YS, Jung HS et al (2006) An orally administered multi-target tyrosine kinase inhibitor, SU11248, is a novel potent inhibitor of thyroid oncogenic RET/papillary thyroid cancer kinases. J Clin Endocrinol Metab 91:4070–4076CrossRefPubMed

Mendel DB, Laird AD, Xin X et al (2003) In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 9:327–337PubMed

Murray LJ, Abrams TJ, Long KR et al (2003) SU11248 inhibits tumor growth and CSF-1R-dependent osteolysis in an experimental breast cancer bone metastasis model. Clin Exp Metastasis 20:757–766CrossRefPubMed

O’Farrell AM, Abrams TJ, Yuen HA et al (2003) SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. Blood 101:3597–3605CrossRefPubMed

Burstein HJ, Elias AD, Rugo HS et al (2008) Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol 26:1810–1816CrossRefPubMed

Socinski MA, Novello S, Brahmer JR et al (2008) Multicenter, phase II trial of sunitinib in previously treated, advanced non-small-cell lung cancer. J Clin Oncol 26:650–656CrossRefPubMed

10.

Bello CL, Sherman L, Zhou J et al (2006) Effect of food on the pharmacokinetics of sunitinib malate (SU11248), a multi-targeted receptor tyrosine kinase inhibitor: results from a phase I study in healthy subjects. Anticancer Drugs 17:353–358CrossRefPubMed

11.

Sakamoto KM (2004) SU-11248 Sugen. Curr Opin Invest Drugs 5:1329–1339

12.

Bello CL, Bu H-Z, Patyna S et al (2007) A phase I mass-balance study to evaluate the metabolism and excretion of [14C]-sunitinib in healthy male subjects. Poster presented at the annual meeting of the American Association for Cancer Research, Los Angeles, 2007 (Abstract 9072)

13.

SUTENT^® prescribing information (revised November 2008) Pfizer Labs, Division of Pfizer Inc., New York. Available at: http://www.sutent.com. Accessed Feb 2009

14.

Demetri DG, George S, Heinrich MC et al (2003) Clinical activity and tolerability of the multi-targeted tyrosine kinase inhibitor SU11248 in patients with malignant gastrointestinal stromal tumors refractory to imatinib mesylate. Presented at the 39th annual meeting of the American Society of Clinical Oncology, Chicago, 31 May–3 June 2003 (Abstract 3273). Available at: http://www.asco.org. Accessed Mar 2009

15.

Rosen L, Mulay M, Long J et al (2003) Phase I trial of SU011248, a novel tyrosine kinase inhibitor in advanced solid tumors. Presented at the 39th annual meeting of the American Society of Clinical Oncology, Chicago, 31 May–3 June 2003 (Abstract 765). Available at: http://www.asco.org. Accessed Mar 2009

16.

Houk BE, Bello CL, Kang D, Amantea M (2009) A population pharmacokinetic meta-analysis of sunitinib malate (SU11248) and its primary metabolite (SU12662) in healthy volunteers and oncology patients. Clin Cancer Res 15:2497–2506CrossRefPubMed

17.

Maki RG, Fletcher JA, Heinrich MC et al (2005) Results from a continuation trial of SU11248 in patients (pts) with imatinib (IM)-resistant gastrointestinal stromal tumor (GIST). Presented at the 41st annual meeting of the American Society of Clinical Oncology, Orlando, 13–17 May 2005 (Abstract 9011). Available at: http://www.asco.org. Accessed Mar 2009

18.

Demetri GD, van Oosterom AT, Garrett CR et al (2006) Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 368:1329–1338CrossRefPubMed

19.

Motzer RJ, Michaelson MD, Redman BG et al (2006) Activity of SU11248, a multi-targeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 24:16–24CrossRefPubMed

20.

Motzer RJ, Rini BI, Bukowski RM et al (2006) Sunitinib in patients with metastatic renal cell carcinoma. JAMA 295:2516–2524CrossRefPubMed

21.

Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205–216CrossRefPubMed

22.

Beal SL, Sheiner LB (1998) NONMEM users guides—Part I–VIII. NONMEM Project Group C255, University of California at San Francisco, San Francisco, 1988–1998

23.

Fleming TR, Harrington DP (1991) Counting processes and survival analysis. Wiley Interscience, New York

24.

Gieschke R, Burger HU, Reigner B et al (2003) Population pharmacokinetics and concentration–effect relationships of capecitabine metabolites in colorectal cancer patients. Br J Clin Pharmacol 55:252–263CrossRefPubMed

25.

Sheiner LB (1994) A new approach to the analysis of analgesic drug trials, illustrated with bromfenac data. Clin Pharmacol Ther 56:309–322CrossRefPubMed

26.

Claret L, Girard P, Zuideveld KP et al (2006) A longitudinal model for tumor growth size measurement in clinical oncology studies. Presented at the 15th annual meeting of the Population Approach Group in Europe, Bruges, Belgium, 14–16 June 2006 (Abstract 1004). Available at: http://www.page-meeting.org/page/page2006/P2006II_10.pdf. Accessed Mar 2009

27.

Mould DR, Holford NH, Schellens JH et al (2002) Population pharmacokinetic and adverse event analysis of topotecan in patients with solid tumors. Clin Pharmacol Ther 71:334–348CrossRefPubMed

28.

Kowalski KG, McFadyen L, Hutmacher MM et al (2003) A two-part mixture model for longitudinal adverse event severity data. J Pharmacokinet Pharmacodyn 30:315–336CrossRefPubMed

29.

Wahlby U, Matolcsi K, Karlsson MO et al (2004) Evaluation of type I error rates when modeling ordered categorical data in NONMEM. J Pharmacokinet Pharmacodyn 31:61–74CrossRefPubMed

Title: Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic meta-analysis
Authors: Brett E. Houk
Carlo L. Bello
Bill Poland
Lee S. Rosen
George D. Demetri
Robert J. Motzer
Publication date: 01-07-2010
Publisher: Springer-Verlag
Published in: Cancer Chemotherapy and Pharmacology / Issue 2/2010
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI: https://doi.org/10.1007/s00280-009-1170-y

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 2/2010

Pre-operative chemotherapy for colorectal cancer liver metastases: an update of recent clinical trials

Do 5-fluorouracil therapies alter CYP2C19 metaboliser status?

Preclinical study of prolonged administration of trastuzumab as combination therapy after disease progression during trastuzumab monotherapy

A phase I study of imexon plus gemcitabine as first-line therapy for advanced pancreatic cancer

Cisplatin administration following carboplatin desensitization failure in primary peritoneal cancer: a brief report

Early alterations in heart gene expression profiles associated with doxorubicin cardiotoxicity in rats

Keynote webinar | Spotlight on antibody–drug conjugates in cancer